Program
AltSonflex1-2-3
Also written as “altSonflex1-2-3 Dose A”, “altSonflex1-2-3 Dose B” and “altSonflex1-2-3 Dose C”.
Its studies are mostly in Diarrhea, led by GlaxoSmithKline.
Furthest: phase 2, since Sep 29, 20213 company-led studies, 1 open or runningNext primary completion: Oct 16, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 31 open or running | phase 2since Sep 29, 2021 | Sep 29, 2021 | Oct 16, 2028phase 2 · NCT07320716 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2021First study: phase 2 study in DiarrheaFirst studyNCT05073003 · 551 enrolled · Belgium, Kenya
- Oct 25, 2024Phase 2 study in DiarrheaNCT06663436 · 200 enrolled · Kenya
- Dec 22, 2025Phase 2 study in DiarrheaNCT07320716 · 179 planned · Kenya
Ahead
- Oct 16, 2028Primary completion: phase 2 study in DiarrheaNCT07320716
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07320716Diarrhea · Kenya | 2 | Recruiting | Oct 16, 2028 | 179 |
| NCT06663436Diarrhea · Kenya | 2 | Completed | Oct 21, 2025 | 200 |
| NCT05073003Diarrhea · Belgium, Kenya | 2 | Completed | Jun 24, 2025 | 551 |
How it is read
Names in the registry
- “AltSonflex1-2-3”, 1 entry
- “altSonflex1-2-3 Dose A”, 1 entry
- “altSonflex1-2-3 Dose B”, 1 entry
- “altSonflex1-2-3 Dose C”, 1 entry
- “AltSonflex1-2-3 High Dose”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.